{"id":390579,"date":"2018-09-25T00:00:00","date_gmt":"2018-09-25T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0009-2018-biopharma-renal-cell-carcinoma-unmet-need-metastatic-renal-cell-carcinoma-us-eu-2018\/"},"modified":"2026-04-15T09:55:47","modified_gmt":"2026-04-15T09:55:47","slug":"unneon0009-2018-biopharma-renal-cell-carcinoma-unmet-need-metastatic-renal-cell-carcinoma-us-eu-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0009-2018-biopharma-renal-cell-carcinoma-unmet-need-metastatic-renal-cell-carcinoma-us-eu-2018\/","title":{"rendered":"Renal Cell Carcinoma | Unmet Need | Metastatic Renal Cell Carcinoma | US\/EU | 2018"},"content":{"rendered":"<p>The treatment armamentarium for renal cell carcinoma mainly comprises small-molecule antiangiogenic inhibitors and immune checkpoint inhibitors. Bristol-Myers Squibb\/Ono Pharmaceutical\u2019s PD-1 inhibitor Opdivo, which was approved for this indication as monotherapy in 2015 and in combination with the CTLA-4 inhibitor Yervoy in 2018, has revolutionized clinical practice. Although existing treatment options aim to improve PFS, significant need remains for well-tolerated therapies that can extend the OS\u00a0and PFS\u00a0of patients with advanced or metastatic renal cell carcinoma.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the treatment drivers that are most likely to influence a therapy\u2019s uptake for advanced or metastatic renal cell carcinoma?<\/li>\n<li>How do current therapies for advanced or metastatic renal cell carcinoma perform on key attributes?<\/li>\n<li>What are the prevailing areas of unmet need and hidden opportunities in this patient population?<\/li>\n<li>What trade-offs are surveyed medical oncologists willing to make across key clinical attributes and price when considering hypothetical new treatment options for advanced or metastatic renal cell carcinoma?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.<\/p>\n","protected":false},"template":"","class_list":["post-390579","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-renal-cell-carcinoma","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390579","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390579\/revisions"}],"predecessor-version":[{"id":393703,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390579\/revisions\/393703"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390579"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}